oramorph 2 mg/ml oraaliliuos
l.molteni & c.dei f.lli alitti societÀ di esercizio s.p.a. - morphine sulphate pentahydrate - oraaliliuos - 2 mg/ml - morfiini
oramorph 20 mg/ml oraaliliuos
l.molteni & c.dei f.lli alitti societÀ di esercizio s.p.a. - morphine sulphate pentahydrate - oraaliliuos - 20 mg/ml - morfiini
oramorph 2 mg/ml oraaliliuos, kerta-annosampulli
l.molteni & c.dei f.lli alitti societÀ di esercizio s.p.a. - morphine sulphate pentahydrate - oraaliliuos, kerta-annosampulli - 2 mg/ml - morfiini
oramorph 6 mg/ml oraaliliuos, kerta-annosampulli
l.molteni & c.dei f.lli alitti societÀ di esercizio s.p.a. - morphine sulphate pentahydrate - oraaliliuos, kerta-annosampulli - 6 mg/ml - morfiini
oramorph 20 mg/ml oraaliliuos, kerta-annosampulli
l.molteni & c.dei f.lli alitti societÀ di esercizio s.p.a. - morphine sulphate pentahydrate - oraaliliuos, kerta-annosampulli - 20 mg/ml - morfiini
bettamousse 1 mg/g vaahto
rph pharmaceuticals ab - betamethasoni valeras - vaahto - 1 mg/g - beetametasoni
naltrexone aop orphan 50 mg tabletti, kalvopäällysteinen
aop orphan pharmaceuticals ag - naltrexoni hydrochloridum - tabletti, kalvopäällysteinen - 50 mg - naltreksoni
besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b: n - polysytemia vera - immunostimulantit, - besremi on tarkoitettu monoterapiana aikuisilla hoitoon polysytemia vera ilman oireenmukainen splenomegalia.
zynlonta
swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastiset aineet - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.
buprenorphine ratiopharm 35 mikrog/tunti depotlaastari
ratiopharm gmbh - buprenorphinum - depotlaastari - 35 mikrog/tunti - buprenorfiini